InvestorsHub Logo
Followers 30
Posts 2777
Boards Moderated 3
Alias Born 10/24/2015

Re: None

Tuesday, 10/15/2019 11:57:20 AM

Tuesday, October 15, 2019 11:57:20 AM

Post# of 77
I did not expect this data [1,2]. It's early, but encouraging. Also, I think the company is under the radar. I like that they are planning to initiate a monotherapy trial for immune-compromised CSCC patient in Q1 next year. Much more to come going forward.

Refs:
1 http://www.globenewswire.com/news-release/2019/10/15/1929577/0/en/Replimune-Provides-Update-on-RP1-Clinical-Development-Program-in-Cutaneous-Squamous-Cell-Carcinoma.html
2 (there are some graphical images) https://ir.replimune.com/static-files/92ceb475-65c1-4086-a461-d3087a568ffe
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent REPL News